Alight adds eMed to partner network to expand employer access to GLP-1 therapies

• Alight added eMed Population Health to its Partner Network to broaden employer-sponsored access to GLP-1 weight-loss therapies.
• Partnership targets scalable programs for eligible employees, with clinical evaluation, treatment access, adherence support, ongoing engagement.
• Offering aims to help employers manage utilization, improve outcomes visibility, reduce avoidable healthcare spending tied to obesity care.
• Gallup data cited: 11% of U.S. adults use GLP-1 drugs for weight loss, up from 3% in 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alight Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811005256) on August 11, 2026, and is solely responsible for the information contained therein.